The New Era of Menopause Treatment Without Hormones
For decades, the conversation about menopause treatment had two lanes — hormone therapy or suffer in silence. If you could not take estrogen, doctors shrugged and handed you a pamphlet about layered clothing and avoiding spicy food. That era is over. Between May 2023 and early 2026, the FDA approved two entirely new drug classes for hot flashes, the British Menopause Society released updated non-hormonal treatment guidelines, and the evidence for cognitive behavioral therapy crossed the threshold from “promising” to “NICE-recommended.” This is the complete guide to every non-hormonal option available right now, ranked by evidence strength, including who should use each one and exactly what the studies show.
The NK3 Revolution: Fezolinetant (Veozah) and Elinzanetant (Lynkuet)
The single biggest development in menopause treatment without hormones in the past five years is the neurokinin-3 (NK3) receptor antagonist class. These drugs do not touch estrogen receptors at all. They block a brain pathway called the neurokinin B/NK3R signaling system, which overheats when estrogen drops. Fezolinetant, sold as Veozah, was FDA-approved in May 2023 for moderate to severe vasomotor symptoms. The pivotal SKYLIGHT 1 and SKYLIGHT 2 trials enrolled 1,028 women across 52 weeks and showed that a once-daily 45-milligram dose reduced hot flash frequency by roughly 60 percent by week 12 — a reduction significantly greater than placebo. The most common side effects were headache and mild gastrointestinal upset. Liver enzyme monitoring is recommended every three months for the first year because a small number of participants showed transient transaminase elevations.
Then came elinzanetant, developed by Bayer, which blocks both NK3 and NK1 receptors. The OASIS 1 and OASIS 2 phase 3 trials, published in JAMA in late 2024, showed that elinzanetant reduced hot flash frequency by roughly 65 to 70 percent at 12 weeks — slightly better than fezolinetant on raw numbers, though no head-to-head trial exists. The OASIS 3 52-week extension confirmed sustained efficacy and tolerability. Elinzanetant received FDA approval as Lynkuet in early 2025 and MHRA approval in the UK in late 2025. Combined, these two drugs represent the first non-hormonal treatments specifically designed for vasomotor symptoms — not borrowed from psychiatry, neurology, or urology. They are not cheaper than antidepressants, at roughly $550 per month without insurance in the US, but they are targeted. For breast cancer survivors on aromatase inhibitors, the OASIS 4 trial showed significant VMS reduction specifically in this population.
SSRIs and SNRIs: The Antidepressants With a Second Job
Before the NK3 drugs existed, the best evidence-based non-hormonal option for hot flashes was a low dose of certain antidepressants. The only FDA-approved SSRI for vasomotor symptoms is paroxetine mesylate (Brisdelle), at 7.5 milligrams daily — one-quarter the dose used for depression. The approval came from two 12-week randomized trials showing a 50 to 60 percent reduction in hot flash frequency compared to roughly 36 percent for placebo. But paroxetine has a problem: it interacts with tamoxifen by inhibiting CYP2D6, the liver enzyme that converts tamoxifen into its active metabolite endoxifen. For breast cancer survivors taking tamoxifen, paroxetine is the wrong choice.
Venlafaxine (Effexor XR), an SNRI, is the go-to alternative. The MsFLASH research network, which ran a landmark 2014 trial comparing multiple non-hormonal treatments, found that venlafaxine 75 milligrams daily reduced hot flash frequency by about 47 percent — comparable to gabapentin but less effective than estrogen. The numbers are real but modest: women who started with eight to ten hot flashes a day typically saw that cut to four or five. Citalopram (Celexa) and escitalopram (Lexapro) have also shown benefit in smaller randomized trials, with the 2011 FREEDOM trial showing a 50 percent reduction on citalopram 20 milligrams. The trade-off with any SSRI or SNRI is side effects: nausea in the first week, sexual dysfunction in roughly 20 to 30 percent of users, and dry mouth. These are not trivial, but for women who cannot take hormones, they are often worth accepting.
Gabapentin and Pregabalin: Nerve Pain Drugs That Antichill
Gabapentin was originally developed for seizure disorders and nerve pain, but it has a robust evidence base for hot flashes. The MsFLASH network’s 2014 comparison trial found that gabapentin 2,400 milligrams daily (divided into three doses) reduced hot flash frequency by about 49 percent — almost identical to venlafaxine. A 2006 Mayo Clinic randomized trial by Dr. Trupti Garg and colleagues showed that gabapentin 900 milligrams daily reduced hot flash severity scores by 66 percent compared to 38 percent for placebo. The mechanism is not fully understood but appears to involve calcium channel modulation in the hypothalamus.
The problem is dosing. Gabapentin requires titration up over two to three weeks to avoid sedation and dizziness. A standard start is 300 milligrams at bedtime, then 300 milligrams twice daily, up to 300 milligrams three times daily. Many women cannot tolerate the 2,400-milligram max dose because the side effects — drowsiness, unsteady gait, peripheral edema — become too much. Pregabalin (Lyrica) works similarly but has less data for hot flashes specifically. Gabapentin is an excellent choice for women who also have migraine with aura, restless legs, or insomnia, because it serves double duty for those conditions. It is not a good choice for women who drive heavy machinery or who already struggle with balance.
Oxybutynin: The Bladder Drug That Cools the Body
Of all the non-hormonal options, oxybutynin may be the most surprising. It is an anticholinergic medication approved for overactive bladder, but multiple studies have shown it reduces hot flashes by 50 to 70 percent — efficacy that rivals the NK3 drugs on some measures. A 2021 meta-analysis in Menopause journal found that extended-release oxybutynin at 15 milligrams daily produced a 64 percent reduction in hot flash frequency. A 2026 American Society of Clinical Oncology abstract evaluating oxybutynin across cancer and non-cancer populations confirmed a consistent and clinically meaningful benefit, though it also noted that anticholinergic burden is a real concern, especially for older women.
The catch is cognitive risk. Anticholinergic medications, especially with prolonged use, are linked to higher rates of dementia in population studies. The 2015 JAMA Neurology study by Dr. Shelly Gray and the Adult Changes in Thought group found that higher cumulative anticholinergic use was associated with a 50 percent increased dementia risk. For a woman who needs non-hormonal treatment for two to three years of severe hot flashes, oxybutynin at the lowest effective dose (2.5 to 5 milligrams daily) may be acceptable. For a woman in her late sixties or early seventies, the risk-to-benefit calculation shifts against it. Do not take oxybutynin for hot flashes without a conversation about anticholinergic load with your prescriber.
Clonidine: The Old Blood Pressure Drug With a Small Evidence Pocket
Clonidine, a central alpha-2 agonist used for hypertension, has clinical-trial evidence for hot flashes dating back to the 1980s. It works by reducing the body’s sympathetic outflow, which in theory should reduce the flushing response. The data, however, is modest. A 2003 Cochrane review found that clonidine reduced hot flash frequency by about 20 to 30 percent — less than any other pharmacologic option listed here. The side effects are not trivial: dry mouth in 40 percent of users, constipation, drowsiness, and the risk of rebound hypertension if stopped abruptly. Clonidine retains a small niche for women with concurrent high blood pressure that is not well-controlled, but the 2025 BMS consensus statement on non-hormonal treatments places it as a third-line option behind NK3 antagonists, SSRIs/SNRIs, gabapentin, and oxybutynin.
Cognitive Behavioral Therapy and Clinical Hypnosis
Non-drug options for non-hormonal menopause treatment for hot flashes have stronger evidence than most physicians realize. Cognitive behavioral therapy adapted for menopause, specifically CBT for vasomotor symptoms, has been tested in multiple randomized trials. The MSFLASH CBT trial published in 2019 showed that a structured group program of six weekly sessions reduced hot flash interference by 67 percent — meaning women who still had hot flashes were significantly less bothered by them. They had learned paced breathing, cognitive restructuring for the “I am flaming out loud” panic, and practical cooling strategies. CBT does not make hot flashes go away. It makes them smaller in your life.
Clinical hypnosis has even more striking data. Dr. Gary Elkins and colleagues at Baylor University ran a 2013 randomized controlled trial in which five weekly hypnosis sessions reduced hot flash frequency by 74 percent and hot flash severity by 68 percent — numbers that rival drug treatment. A 2020 follow-up showed that the benefit persisted at 12 weeks post-treatment. The mechanism appears to involve reduced sympathetic activation and altered thermoregulatory perception. The North American Menopause Society (NAMS) now includes clinical hypnosis as a recommended non-hormonal option in its position statement. The limiting factor is access — trained menopause-adapted hypnosis practitioners are rare outside of academic medical centers.
Exercise, Diet, and Cooling Strategies
Lifestyle changes are the most recommended and least studied non-hormonal interventions. The evidence for structured exercise as a hot flash treatment is surprisingly mixed. The MSFLASH exercise trial, which randomized women to a 12-week supervised aerobic program versus usual activity, found that exercise improved sleep quality and mood but did not reduce hot flash frequency. That result disappointed many clinicians. However, a 2024 systematic review in Climacteric found that yoga and resistance training improved hot flash bother scores, even if frequency did not change. Weight loss is the one lifestyle factor with consistent hot flash data. The Women’s Health Initiative observational analysis showed that women who lost 10 pounds or more during the study had significantly lower odds of reporting hot flashes at follow-up. The mechanism is clear: adipose tissue produces estrogen precursors, and losing fat reduces circulating estrogen, but it also reduces the body’s core insulation, which stabilizes temperature regulation.
Dietary triggers matter. Alcohol, caffeine, and spicy foods are the three most commonly reported triggers, and the data from several survey-based studies suggest that simply keeping a symptom diary and eliminating your personal triggers reduces hot flash bother by 15 to 25 percent — modest but free. Paced breathing, also called slow deep breathing, has one solid trial: a 2010 study by Dr. Robert Freedman and colleagues showed that slow diaphragmatic breathing reduced hot flash frequency by about 40 percent compared to no intervention. The mechanism is thought to be reduced sympathetic activation. It takes about 15 minutes of practice twice daily to get the hang of it.
Supplements and Herbal Remedies: The Evidence Vacuum
This is the part where the evidence collapses. Soy isoflavones, the most studied supplement for menopause symptoms, have produced wildly inconsistent results across more than 40 clinical trials. A 2023 Cochrane review found that soy isoflavones reduced hot flash frequency by roughly 15 to 25 percent compared to placebo — statistically significant but clinically marginal. The problem is the enormous heterogeneity in response. About 30 percent of women are “equol producers” — their gut bacteria can convert daidzein into equol, a compound that binds estrogen receptors. Equol producers may benefit; non-producers get nothing. There is no simple at-home test to know which group you are in.
Black cohosh, the bestselling menopause herbal remedy in the United States, failed to beat placebo in the largest and most rigorous trial conducted: the 2006 Herbal Alternatives for Menopause Trial (HALT), funded by the NIH, showed that black cohosh was no better than placebo for hot flash frequency or severity over one year. That trial was designed by Dr. Katherine Newton and the Group Health Cooperative researchers and enrolled 351 women. Red clover, evening primrose oil, and dong quai have similarly failed to outperform placebo in randomized trials. Vitamin E at 800 international units daily produces a minimal effect — roughly one fewer hot flash per day — but the dose is high enough that the SELECT trial raised concerns about vitamin E and prostate cancer risk, though that was in a male population. For women determined to try supplements despite the evidence, herbal remedies for menopause like isoflavones at 50 to 100 milligrams daily probably will not cause harm, but they should not replace treatments with proven efficacy.
Who Absolutely Needs Non-Hormonal Treatment
Three groups of women have no real choice but to pursue menopause treatment without hormones. The first is breast cancer survivors with hormone-receptor-positive tumors. Menopause after breast cancer is often abrupt, severe, and driven by chemotherapy-induced ovarian failure or aromatase inhibitors. Estrogen is contraindicated. The OASIS 4 trial of elinzanetant specifically studied this group and showed meaningful VMS reduction, making it the most promising option. The second group is women with a history of venous thromboembolism (blood clots) or known thrombophilia — the 2017 Cochrane review confirms that oral hormone therapy roughly doubles VTE risk in predisposed women. The third group is women with estrogen-sensitive cancers other than breast, including some endometrial and ovarian cancers, and women with migraine with aura, where estrogen-based contraception is contraindicated due to stroke risk (though transdermal low-dose HRT may still be considered under specialist guidance). For all three groups, the decision is not “should I treat my menopause without hormones?” but “which non-hormonal option is best for my specific medical history?”
Menopause HRT after breast cancer is generally not an option, but the non-hormonal pathway has more tools than most oncologists discuss with their patients. Cognitive behavioral therapy, venlafaxine, gabapentin, and the NK3 drugs all have data specifically in breast cancer populations. The limiting factor is not available science — it is physician awareness.
Building Your Personal Non-Hormonal Treatment Plan
The hierarchy of evidence for non-hormonal options in 2026 looks like this, ranked by effect size from highest to lowest: NK3 receptor antagonists (Veozah and Lynkuet) at roughly 60 to 70 percent reduction; oxybutynin at roughly 50 to 70 percent reduction but with anticholinergic concerns; SSRIs/SNRIs at roughly 45 to 55 percent reduction; gabapentin at roughly 45 to 50 percent reduction; clinical hypnosis at roughly 70 percent reduction but with access limitations; CBT at roughly 50 to 60 percent reduction in symptom bother; lifestyle changes at roughly 15 to 25 percent reduction; supplements at roughly 10 to 20 percent reduction. These numbers come from different trial populations and different measurement tools, so the comparisons are approximate — but the ordering is consistent across systematic reviews.
The practical takeaway is straightforward. If your hot flashes are severe enough to interrupt sleep and function, start with the highest-evidence tier that fits your medical profile. For most women without contraindications to estrogen, the most effective treatment remains hormone therapy. But if hormones are off the table, you have better options in 2026 than any previous generation of women in menopause. Do not settle for layered clothing and a sympathetic pat on the shoulder. The science has caught up.